Equity Mates podcast with Michael Frazis mentions OCC at 28mins (transcript) and an announcement of two new executive US appointments from Axogen who are the incumbent in the field of nerve repair.

Orthocell has appointed two experienced US-based executives, John Walker and Phillip Edmondson, to

drive the market launch and sales of Remplir™ following the expected US FDA approval in the first

quarter of 2025.

John Walker, Vice President - Sales 

Mr Walker is a high-performing sales executive with over 25 years’ experience in various senior salesforce

leadership and operational roles in the orthopaedic, primarily peripheral nerve repair, medical device sector. 

Most recently, Mr Walker was the Area Vice President and Director of Sales for USA and Europe at Axogen. 

Mr Walker was one of the highly awarded leaders at Axogen, leading the growth of nerve repair device sales. 

Mr Walker is based in Texas and will commence US launch preparations immediately. 

Phillip Edmondson, Vice President - Medical Affairs

Mr Edmondson is an experienced medical affairs and sales executive with over 18 years’ experience in various

senior medical device sales and education roles in the medical device, pharmaceutical, and biologics sectors. 

Mr Edmondson was the Senior Medical Affairs Manager and Sales Account Manager at Axogen where he

developed, implemented, and monitored Axogen’s academic program strategy. Mr Edmondson was the

primary liaison with academic institutions, Residency and Fellowship Directors, surgical trainees and key

opinion leaders (KOLs) and received multiple awards and recognition for his outstanding sales growth

performance and leadership. Mr Edmondson is based in Florida and will commence US launch preparations

immediately.